AD dementia risk in late MCI, in early MCI, and in subjective memory impairment

Jessen, Frank; Wolfsgruber, Steffen; Wiese, Birgitt; Bickel, Horst; Mösch, Edelgard; Kaduszkiewicz, Hanna; Pentzek, Michael; Riedel‐Heller, Steffi G.; Luck, Tobias; Fuchs, Ângela; Weyerer, Siegfried; Werle, Jochen; Bussche, Hendrik van den; Scherer, Martin; Maier, Wolfgang; Wagner, Michael

doi:10.1016/j.jalz.2012.09.017

Cited by 437 publications

(373 citation statements)

References 32 publications

Supporting

Mentioning

353

Contrasting

Unclassified

Order By: Relevance

“…MCI has been defined as both subjective and objective cognitive impairment in patients without dementia (Petersen et al, 2014). The risk for converting to dementia from SCI or MCI has been estimated to 10% and 25-40% respectively, depending on study design, duration of the follow up, and population type (clinic-based or general population) (Maioli et al, 2007) (Jessen et al, 2014b) (Mitchell et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

Enache

Solomon

Cavallin

et al. 2016

Neurobiology of Aging

View full text Add to dashboard Cite

PostprintThis is the accepted version of a paper published in Neurobiology of Aging. This paper has been peerreviewed but does not include the final publisher proof-corrections or journal pagination. Citation for the original published paper (version of record):Enache, D., Solomon, A., Cavallin, L., Kåreholt, I., Kramberger, M G. et al. (2016) CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. Neurobiology of Aging AbstractThe aim of this study was to explore cross-sectional associations between CAIDE Dementia Risk Score and dementia-related CSF and neuroimaging biomarkers in 724 memory clinic patients without dementia from the Memory Clinic at Karolinska University Hospital Huddinge, Sweden. We additionally evaluated the score's capacity to predict dementia. Two risk score versions were calculated: one including age, gender, obesity, hyperlipidaemia, and hypertension; and one additionally including APOE ε4 carrier status. CSF was analysed for amyloid β (Aβ), total tau (t-tau), and phosphorylated tau (p-tau). Visual assessments of medial temporal lobe atrophy (MTA), global cortical atrophy-frontal subscale (GCA-F) and Fazekas scale for white matter changes (WMC) were performed. Higher CAIDE Dementia Risk Score (version without APOE) was significantly associated with higher t-tau, more severe MTA, WMC and GCA-F. Higher CAIDE Dementia Risk Score (version with APOE) was associated with reduced Aβ, more severe MTA and WMC. CAIDE Dementia Risk Score version with APOE seemed to predict dementia better in this memory clinic population with short follow-up than the version without APOE.3

show abstract

Section: Introductionmentioning

confidence: 99%

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

Enache

Solomon

Cavallin

et al. 2016

Neurobiology of Aging

View full text Add to dashboard Cite

show abstract

“…SCD was defined if participants were cognitively unimpaired and stated to have decline in cognitive functioning unrelated to an event or condition explaining the cognitive deficits according to recent research criteria 11 . HC individuals never reported SCD and had no history of neurological or psychiatric disease or any sign of cognitive decline.…”

Section: Methodsmentioning

confidence: 99%

“…SCD is actually considered to be associated with an increased likelihood of future cognitive impairment and dementia, especially in those cases with worry about memory [8][9][10] . According to the suggestions made by the Working Group of the Subjective Cognitive Decline Initiative (SCD-I) 11 , SCD is defined as personal complaints about ones' cognitive state in the absence of objective cognitive impairment. This definition of SCD was also used in the present study.…”

mentioning

confidence: 99%

[P3–218]: Tau Plasma Levels in Subjective Cognitive Decline: Results From the Delcode Study

Laske

Preische

Goepfert

et al. 2017

Alzheimer's & Dementia

Self Cite

View full text Add to dashboard Cite

Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age-and gendermatched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = −0.179; p = 0.240), and p-tau181 (r = −0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.Brain deposition of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau is a hallmark of Alzheimer's disease (AD) pathology 1 . Several tau tracers for positron emission tomography (PET) imaging including 18F-TH523 have been developed over the past few years 2 . As in the brain itself, tau levels in the cerebrospinal fluid (CSF) were found to be increased in AD patients 3 . Therefore, CSF tau provides a useful marker of tau pathology. Several tau-based therapeutic approaches are currently investigated. Thus, detection of tau levels holds enormous potential for both early diagnosis of AD and monitoring of disease-modifying therapeutics.

show abstract

“…According to the suggestions made by the Working Group of the Subjective Cognitive Decline Initiative (SCD-I) [4], SCD is defined as personal complaints about one´s cognitive state in the absence of objective cognitive impairment. This definition of SCD was also used in the present study.…”

Section: Introductionmentioning

confidence: 99%

Worries about Alzheimer’s Disease and Subjective Cognitive Decline in Proxies of AD Patients and Controls

Philipps¹,

Müller²,

Preische³

et al. 2017

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

AD dementia risk in late MCI, in early MCI, and in subjective memory impairment

Abstract: SMI and EMCI with self-reported concerns were associated with the same risk of AD dementia, suggesting that pre-LMCI risk conditions should be extended to SMI with concerns.

Cited by 437 publications

References 32 publications

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

[P3–218]: Tau Plasma Levels in Subjective Cognitive Decline: Results From the Delcode Study

Worries about Alzheimer’s Disease and Subjective Cognitive Decline in Proxies of AD Patients and Controls

Contact Info

Product

Resources

About